Protective effects of trimetazidine on bone marrow mesenchymal stem cells viability in an ex vivo model of hypoxia and in vivo model of locally myocardial ischemia

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 32, Issue 1, 2012, Pages 36-41

  Xu, Hongxin ^a   Zhu, Gangyan ^a   Tian, Yihao ^b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Bone marrow mesenchymal stem cells; Myocardial ischemia; Trimetazidine; Viability

Indexed keywords

CARDIOTONIC AGENT; TRIMETAZIDINE; VASODILATOR AGENT;

ANIMAL; ARTICLE; CELL HYPOXIA; CELL SURVIVAL; CYTOLOGY; DRUG EFFECT; HEART MUSCLE ISCHEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; RAT; WISTAR RAT;

ANIMALS; CARDIOTONIC AGENTS; CELL HYPOXIA; CELL SURVIVAL; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MYOCARDIAL ISCHEMIA; RATS; RATS, WISTAR; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 84861157772     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-012-0006-x     Document Type: Article

References (28)

1. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation, 1993, 88(1):107-115
2. Makino S, Fukuda K, Miyoshi S, et al. Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest, 1999, 103(5):697-705
3. Song H, Kwon K, Lim S, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. Mol Cells, 2005, 19(3):402-407
4. Bianchi G, Banfi A, Mastrogiacomo M, et al. Ex vivo enrichment of mesenchymal cell progenitors by fibroblast growth factor 2. Exp Cell Res, 2003, 287(1):98-105
5. Mangi AA, Noiseux N, Kong D, et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat Med, 2003, 9(9): 1195-1201
6. Maridonneau PI, Harpey C. Effects of trimetazidine on membrane damage reduced by oxygen free radicals in human red cells. Br J Clin Pharmacol, 1985, 20(2): 148-151
7. Maupoil V, Rochette L, Tabard A, et al. Direct measurement of free radical generation in isolated rat heart by electron paramagnetic resonance spectroscopy: effect of trimetazidine. Adv Exp Med Biol, 1990, 264:373-376
8. Reymond F, Steyaert G, Carrupt PA, et al. The pH-partition profile of the anti-ischemic drug trimetazidine may explain its reduction of intracellular acidosis. Pharm Res, 1999, 16(5):616-624
9. Renaud JF. Internal pH, Na+, and Ca2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther, 1988, 1(6):677-686
10. Salducci MD, Chauvet-Monges AM, Tillement JP, et al. Trimetazidine reverses calcium accumulation and impairment of phosphorylation induced by cyclosporine A in isolated rat liver mitochondria. J Pharmacol Exp Ther, 1996, 277(1):417-422
11. Wang JS, Shum-Tim D, Galipeau J, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg, 2000, 120(5):999-1006
12. Suzuki K, Smolenski RT, Jayakumar J, et al. Heat shock treatment enhances graft cell survival in skeletal myoblast transplantation to the heart. Circulation, 2000, 102(19 Suppl 3):III216-221
13. Jiang S, Haider HKh, Idris NM, et al. Supportive interaction between cell survival signaling and angiocompetent factors enhances donor cell survival and promotes angiomyogenesis for cardiac repair. Circ Res, 2006, 99(7): 776-784
14. Gnecchi M, He H, Noiseux N, et al. Evidence supporting paracrine hypothesis for Akt-modified mesenchymal stem cell-mediated cardiac protection and functional improvement. FASEB J, 2006, 20(6):661-669
15. Li W, Ma N, Ong LL, et al. Bcl-2 engineered MSCs inhibited apoptosis and improved heart function. Stem Cells, 2007, 25(8):2118-2127
16. Bartunek J, Croissant JD, Wijins W, et al. Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium. Am J Physiol Heart Circ Physiol, 2007, 292(2):H1095-1104
17. Tang YL, Tang Y, Zhang YC, et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia- regulated heme oxygenase-1 vector. J Am Coll Cardiol, 2005, 46(7):1339-1350
18. Jo JI, Nagaya N, Miyahara Y, et al. Transplantation of genetically engineered mesenchymal stem cells improves cardiac function in rats with myocardial infarction: benefit of a novel nonviral vector, Cationized Dextran. Tissue Eng, 2007, 13(2):313-322
19. Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol, 1995, 76(6):41B-44B
20. Di Pasquale P, Lo Verso P, Bucca V, et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther, 1999, 13(5): 423-428
21. Freude B, Masters TN, Robicsek F, et al. Apoptosis is initiated by myocardial ischemia and executed during reperfusion. J Mol Cell Cardiol, 2000, 32(2):197-208
22. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science, 1995, 267(5203):1456-1462
23. Entman ML, Michael L, Rossen RD, et al. Inflammation in the course of early myocardial ischemia. FASEB J, 1991, 5(11):2529-2537
24. Kaminski KA, Bonda TA, Korecki J, et al. Oxidative stress and neutrophil activation-the two keystones of ischemia/reperfusion injury. Int J Cardiol, 2002, 86(1): 41-59
25. Tokuda H, Kozawa O, Uematsu T. Basic fibroblast growth factor stimulates vascular endothelial growth factor release in osteoblasts: divergent regulation by p42/p44 mitogen-activated protein kinase and p38 mitogen- activated protein kinase. J Bone Miner Res, 2000, 15(12):2371-2379
26. Nugent MA, Iozzo RV. Fibroblast growth factor-2. Int J Biochem Cell Biol, 2000, 32(2):115-120
27. Debiais F, Lefevre G, Lemonnier J, et al. Fibroblast growth factor-2 induces osteoblast survival through a phosphatidylinositol 3-kinase-dependent- beta-catenin-independent signaling pathway. Exp Cell Res, 2004, 297(1)235-246
28. Lopaschuk GD. Optimising cardiac energy metabolism: how can fatty acid and carbohydrate metabolism be manipulated? Coronary Artery Dis, 2001, 12(Suppl 1):8-11